ValuEngine Upgrades Acadia Healthcare (ACHC) to “Sell”

Acadia Healthcare (NASDAQ:ACHC) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Wednesday, ValuEngine reports.

A number of other analysts also recently issued reports on ACHC. Zacks Investment Research raised shares of Acadia Healthcare from a “sell” rating to a “hold” rating in a report on Thursday, January 24th. BidaskClub raised shares of Acadia Healthcare from a “strong sell” rating to a “sell” rating in a report on Thursday, March 21st. Robert W. Baird decreased their price objective on shares of Acadia Healthcare from $40.00 to $38.00 and set a “neutral” rating on the stock in a report on Monday, March 4th. Citigroup decreased their price objective on shares of Acadia Healthcare from $43.00 to $38.00 and set a “buy” rating on the stock in a report on Monday, March 4th. Finally, Deutsche Bank began coverage on shares of Acadia Healthcare in a report on Thursday, January 3rd. They set a “hold” rating and a $27.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $37.20.

Shares of NASDAQ ACHC opened at $32.09 on Wednesday. Acadia Healthcare has a 1 year low of $24.27 and a 1 year high of $45.35. The firm has a market cap of $2.76 billion, a P/E ratio of 14.33, a PEG ratio of 1.77 and a beta of 0.67. The company has a current ratio of 1.08, a quick ratio of 1.08 and a debt-to-equity ratio of 1.35.

Acadia Healthcare (NASDAQ:ACHC) last announced its quarterly earnings results on Thursday, February 28th. The company reported $0.47 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.47. Acadia Healthcare had a negative net margin of 5.83% and a positive return on equity of 7.54%. The firm had revenue of $743.55 million for the quarter, compared to the consensus estimate of $743.05 million. On average, research analysts anticipate that Acadia Healthcare will post 2.18 EPS for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its stake in shares of Acadia Healthcare by 3.5% during the third quarter. JPMorgan Chase & Co. now owns 6,033,366 shares of the company’s stock worth $212,375,000 after purchasing an additional 204,401 shares during the period. Credit Suisse AG increased its stake in Acadia Healthcare by 4.6% during the 3rd quarter. Credit Suisse AG now owns 61,730 shares of the company’s stock worth $2,173,000 after acquiring an additional 2,712 shares during the period. Paloma Partners Management Co bought a new position in Acadia Healthcare during the 3rd quarter worth $411,000. The Manufacturers Life Insurance Company increased its stake in Acadia Healthcare by 11.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 146,238 shares of the company’s stock worth $5,148,000 after acquiring an additional 14,877 shares during the period. Finally, Man Group plc increased its stake in Acadia Healthcare by 8.0% during the 3rd quarter. Man Group plc now owns 202,547 shares of the company’s stock worth $7,130,000 after acquiring an additional 15,074 shares during the period.

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities, and outpatient behavioral healthcare facilities to serve the behavioral health and recovery needs of communities. The company operates acute inpatient psychiatric facilities, which offer evaluation and crisis stabilization of patients with severe psychiatric diagnoses; specialty treatment facilities, including residential recovery facilities, eating disorder facilities, and comprehensive treatment centers that provide continuum care for adults with addictive disorders and co-occurring mental disorders; and residential treatment centers, which treat patients with behavioral disorders in a non-hospital setting, including outdoor programs.

See Also: What are momentum indicators and what do they show?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Acadia Healthcare (NASDAQ:ACHC)

Receive News & Ratings for Acadia Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.